Skip to content
2000
Volume 26, Issue 2
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic viral therapy, has transformed cancer immunotherapy since its 2015 approval for unresectable melanoma. Engineered from Herpes Simplex Virus type 1 (HSV-1) with deletions in ICP34.5 and ICP47 genes and GM-CSF insertion, T-VEC selectively replicates within the tumor cells, inducing lysis and releasing tumor-derived antigens while stimulating systemic antitumor immunity through dendritic cell activation. Although extensively studied for melanoma, its potential extends beyond this malignancy, with emerging applications in breast cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and other solid tumors. This review synthesizes T-VEC’s mechanism of action, leveraging dysregulated Ras signalling, impaired interferon pathways in cancer cells, its clinical outcomes, and safety profile across these indications. While prior literature emphasizes melanoma monotherapy and combinations with immune checkpoint inhibitors, less attention has been given to its efficacy in non-melanoma cancers and synergistic potential with chemotherapy or radiation therapy. By exploring recent trials, such as T-VEC with neoadjuvant chemotherapy in triple-negative breast cancer and pembrolizumab in HNSCC, highlighting its versatility. Comparative analysis with other oncolytic viruses like HF-10, oncorine (H101), and measles virus variants positions T-VEC within the virotherapy landscape. Key challenges—systemic delivery, immune clearance, and biomarker development for patient selection—are addressed alongside strategies to enhance immune modulation through novel combinations. This review underscores T-VEC’s expanding role in cancer treatment, offering clinicians’ and researchers’ insights to optimize its therapeutic horizons across diverse malignancies.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206379105250429115604
2025-05-06
2026-03-05

  • From This Site

    /content/journals/acamc/10.2174/0118715206379105250429115604
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KellyE. RussellS.J. History of oncolytic viruses: Genesis to genetic engineering.Mol. Ther.200715465165910.1038/sj.mt.6300108 17299401
     [Google Scholar]
  2. FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma.Frederick, MarylandNational Cancer Institute201519
     [Google Scholar]
  3. LiuB.L. RobinsonM. HanZ-Q. BranstonR.H. EnglishC. ReayP. McGrathY. ThomasS.K. ThorntonM. BullockP. LoveC.A. CoffinR.S. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.Gene Ther.200310429230310.1038/sj.gt.3301885 12595888
     [Google Scholar]
  4. FerrucciP.F. PalaL. ConfortiF. CocorocchioE. Talimogene laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma.Cancers2021136138310.3390/cancers13061383 33803762
     [Google Scholar]
  5. HamidO. HoffnerB. GasalE. HongJ. CarvajalR.D. Oncolytic immunotherapy: Unlocking the potential of viruses to help target cancer.Cancer Immunol. Immunother.201766101249126410.1007/s00262‑017‑2025‑8 28712033
     [Google Scholar]
  6. YokotaY. InoueH. MatsumuraY. NabetaH. NarusawaM. WatanabeA. SakamotoC. HijikataY. Iga-MurahashiM. TakayamaK. SasakiF. NakanishiY. YokomizoT. TaniK. Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF–induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems.Blood2012120173444345410.1182/blood‑2011‑10‑383240 22936657
     [Google Scholar]
  7. KohlhappF.J. KaufmanH.L. Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy.Clin. Cancer Res.20162251048105410.1158/1078‑0432.CCR‑15‑2667 26719429
     [Google Scholar]
  8. AchuthanA.A. LeeK.M.C. HamiltonJ.A. Targeting GM-CSF in inflammatory and autoimmune disorders.Semin. Immunol.20215410152310.1016/j.smim.2021.101523 34776300
     [Google Scholar]
  9. ChukwurahE. FarabaughK.T. GuanB.J. RamakrishnanP. HatzoglouM. A tale of two proteins: PACT and PKR and their roles in inflammation.FEBS J.2021288226365639110.1111/febs.15691 33387379
     [Google Scholar]
  10. Gal-Ben-AriS. BarreraI. EhrlichM. RosenblumK. PKR: A kinase to remember.Front. Mol. Neurosci.20191148010.3389/fnmol.2018.00480 30686999
     [Google Scholar]
  11. KaufmanH.L. KohlhappF.J. ZlozaA. Oncolytic viruses: A new class of immunotherapy drugs.Nat. Rev. Drug Discov.201514964266210.1038/nrd4663 26323545
     [Google Scholar]
  12. RussellS.J. PengK.W. BellJ.C. Oncolytic virotherapy.Nat. Biotechnol.201230765867010.1038/nbt.2287 22781695
     [Google Scholar]
  13. AthertonM.J. LichtyB.D. Evolution of oncolytic viruses: Novel strategies for cancer treatment.Immunotherapy20135111191120610.2217/imt.13.123 24188674
     [Google Scholar]
  14. HuJ.C.C. CoffinR.S. DavisC.J. GrahamN.J. GrovesN. GuestP.J. HarringtonK.J. JamesN.D. LoveC.A. McNeishI. MedleyL.C. MichaelA. NuttingC.M. PandhaH.S. ShorrockC.A. SimpsonJ. SteinerJ. StevenN.M. WrightD. CoombesR.C. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.Clin. Cancer Res.200612226737674710.1158/1078‑0432.CCR‑06‑0759 17121894
     [Google Scholar]
  15. Skin Cancer.Geneva, SwitzerlandWorld Health Organization202418
     [Google Scholar]
  16. Melanoma Overview; Skin Cancer Foundation.US202419
     [Google Scholar]
  17. Melanoma Skin Cancer.Atlanta, GeorgiaAmerican Cancer Society202416
     [Google Scholar]
  18. GorryC. McCullaghL. O’DonnellH. BarrettS. SchmitzS. BarryM. CurtinK. BeausangE. BarryR. CoyneI. Neoadjuvant treatment for malignant and metastatic cutaneous melanoma.Cochrane Database Syst. Rev.201820183CD012974
     [Google Scholar]
  19. AndtbackaR.H.I. RossM. PuzanovI. MilhemM. CollichioF. DelmanK.A. AmatrudaT. ZagerJ.S. CranmerL. HsuehE. ChenL. ShilkrutM. KaufmanH.L. Patterns of clinical response with talimogene laherparepvec (t-vec) in patients with melanoma treated in the oPTIM phase III clinical trial.Ann. Surg. Oncol.201623134169417710.1245/s10434‑016‑5286‑0 27342831
     [Google Scholar]
  20. HarringtonK. AndtbackaR. CollichioF. DowneyG. ChenL. SzaboZ. KaufmanH. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: Subanalysis of the Phase III OPTiM trial.OncoTargets Ther.201697081709310.2147/OTT.S115245 27895500
     [Google Scholar]
  21. AndtbackaR.H.I. CollichioF. HarringtonK.J. MiddletonM.R. DowneyG. ӦhrlingK. KaufmanH.L. Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma.J. Immunother. Cancer20197114510.1186/s40425‑019‑0623‑z 31171039
     [Google Scholar]
  22. SenzerN.N. KaufmanH.L. AmatrudaT. NemunaitisM. ReidT. DanielsG. GonzalezR. GlaspyJ. WhitmanE. HarringtonK. GoldsweigH. MarshallT. LoveC. CoffinR. NemunaitisJ.J. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.J. Clin. Oncol.200927345763577110.1200/JCO.2009.24.3675 19884534
     [Google Scholar]
  23. AndtbackaR.H.I. CollichioF.A. AmatrudaT. SenzerN.N. ChesneyJ. DelmanK.A. SpitlerL.E. PuzanovI. DolemanS. YeY. VanderwaldeA.M. CoffinR. KaufmanH. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.J. Clin. Oncol.20133118Suppl.LBA9008LBA900810.1200/jco.2013.31.18_suppl.lba9008
     [Google Scholar]
  24. KaufmanH.L. BinesS.D. OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.Future Oncol.20106694194910.2217/fon.10.66 20528232
     [Google Scholar]
  25. KaufmanH.L. KimD.W. DeRaffeleG. MitchamJ. CoffinR.S. Kim-SchulzeS. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Ann. Surg. Oncol.201017371873010.1245/s10434‑009‑0809‑6 19915919
     [Google Scholar]
  26. KaufmanH.L. AndtbackaR.H.I. CollichioF.A. AmatrudaT. SenzerN.N. ChesneyJ. DelmanK.A. SpitlerL.E. PuzanovI. YeY. LiA. GansertJ.L. CoffinR. RossM.I. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte- macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol.,201432(15_suppl)(Suppl.), 9008a-9008a.10.1200/jco.2014.32.15_suppl.9008a
     [Google Scholar]
  27. GreigS.L. Talimogene Laherparepvec: First Global Approval.Drugs201676114715410.1007/s40265‑015‑0522‑7 26620366
     [Google Scholar]
  28. HodiF.S. O’DayS.J. McDermottD.F. WeberR.W. SosmanJ.A. HaanenJ.B. GonzalezR. RobertC. SchadendorfD. HasselJ.C. AkerleyW. van den EertweghA.J.M. LutzkyJ. LoriganP. VaubelJ.M. LinetteG.P. HoggD. OttensmeierC.H. LebbéC. PeschelC. QuirtI. ClarkJ.I. WolchokJ.D. WeberJ.S. TianJ. YellinM.J. NicholG.M. HoosA. UrbaW.J. Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med.2010363871172310.1056/NEJMoa1003466 20525992
     [Google Scholar]
  29. FellnerC. Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use.P. T.2012379503530 23066344
     [Google Scholar]
  30. ChesneyJ. PuzanovI. CollichioF. SinghP. MilhemM.M. GlaspyJ. HamidO. RossM. FriedlanderP. GarbeC. LoganT.F. HauschildA. LebbéC. ChenL. KimJ.J. GansertJ. AndtbackaR.H.I. KaufmanH.L. randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma.J. Clin. Oncol.201836171658166710.1200/JCO.2017.73.7379 28981385
     [Google Scholar]
  31. YamazakiN. IseiT. KiyoharaY. KogaH. KojimaT. TakenouchiT. YokotaK. NamikawaK. YiM. KeeganA. FukushimaS. A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma.Cancer Sci.202211382798280610.1111/cas.15450 35656636
     [Google Scholar]
  32. AndtbackaR.H.I. KaufmanH.L. CollichioF. AmatrudaT. SenzerN. ChesneyJ. DelmanK.A. SpitlerL.E. PuzanovI. AgarwalaS.S. MilhemM. CranmerL. CurtiB. LewisK. RossM. GuthrieT. LinetteG.P. DanielsG.A. HarringtonK. MiddletonM.R. MillerW.H.Jr ZagerJ.S. YeY. YaoB. LiA. DolemanS. VanderWaldeA. GansertJ. CoffinR.S. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J. Clin. Oncol.201533252780278810.1200/JCO.2014.58.3377 26014293
     [Google Scholar]
  33. LouieR.J. PerezM.C. JajjaM.R. SunJ. CollichioF. DelmanK.A. LoweM. SarnaikA.A. ZagerJ.S. OllilaD.W. Real-world outcomes of talimogene laherparepvec therapy: A multi-institutional experience.J. Am. Coll. Surg.2019228464464910.1016/j.jamcollsurg.2018.12.027 30690076
     [Google Scholar]
  34. FrankeV. BergerD.M.S. KlopW.M.C. van der HielB. van de WielB.A. ter MeulenS. WoutersM.W.J.M. van HoudtW.J. van AkkooiA.C.J. High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a).Int. J. Cancer2019145497497810.1002/ijc.32172 30694555
     [Google Scholar]
  35. PerezM.C. MiuraJ.T. NaqviS.M.H. KimY. HolsteinA. LeeD. SarnaikA.A. ZagerJ.S. Talimogene laherparepvec (TVEC) for the treatment of advanced melanoma: A single-institution experience.Ann. Surg. Oncol.201825133960396510.1245/s10434‑018‑6803‑0 30298318
     [Google Scholar]
  36. DummerR. GyorkiD.E. HyngstromJ.R. NingM. LawrenceT. RossM.I. Final 5-year follow-up results evaluating neoadjuvant talimogene laherparepvec plus surgery in advanced melanoma.JAMA Oncol.20239101457145910.1001/jamaoncol.2023.2789 37561473
     [Google Scholar]
  37. Breast Cancer Statistics.United KingdomWorld Cancer Research Fund202415
     [Google Scholar]
  38. Breast Cancer.Geneva, SwitzerlandWorld Health Organization202418
     [Google Scholar]
  39. O’KeefeK. DesaiN. TanA. Treating.Breast Cancer20241651752710.2147/BCTT.S271441 39224861
     [Google Scholar]
  40. KaiM. MarxA.N. LiuD.D. ShenY. GaoH. ReubenJ.M. WhitmanG. KrishnamurthyS. RossM.I. LittonJ.K. LimB. IbrahimN. KogawaT. UenoN.T. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.Sci. Rep.20211112224210.1038/s41598‑021‑01473‑2 34782633
     [Google Scholar]
  41. SolimanH. HogueD. HanH. MooneyB. CostaR. LeeM.C. NiellB. WilliamsA. ChauA. FalconS. KhakpourN. WeinfurtnerR.J. HooverS. KilukJ. RosaM. KhongH. CzernieckiB. A Phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.Clin. Cancer Res.20212741012101810.1158/1078‑0432.CCR‑20‑3105 33219014
     [Google Scholar]
  42. DummerR. HoellerC. GruterI.P. MichielinO. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.Cancer Immunol. Immunother.201766668369510.1007/s00262‑017‑1967‑1 28238174
     [Google Scholar]
  43. HamidO. IsmailR. PuzanovI. Intratumoral Immunotherapy-Update 2019.Oncologist2020253e423e43810.1634/theoncologist.2019‑0438 32162802
     [Google Scholar]
  44. ConryR.M. WestbrookB. McKeeS. NorwoodT.G. Talimogene laherparepvec: First in class oncolytic virotherapy.Hum. Vaccin. Immunother.201814483984610.1080/21645515.2017.1412896 29420123
     [Google Scholar]
  45. HechtJ.R. Abstract P3-09-19: Preliminary safety data of intrahepatic talimogene laherparepvec and intravenous atezolizumab in patients with triple negative breast cancer. Cancer Res.,202080(4_Supplement), 09-19.10.1158/1538‑7445.SABCS19‑P3‑09‑19
  46. HechtJ.R. RamanS.S. ChanA. KalinskyK. BaurainJ.F. JimenezM.M. GarciaM.M. BergerM.D. LauerU.M. KhattakA. CarratoA. ZhangY. LiuK. ChaE. KeeganA. BhattaS. StrassburgC.P. RoohullahA. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.ESMO Open20238210088410.1016/j.esmoop.2023.100884 36863095
     [Google Scholar]
  47. EmensL.A. CruzC. EderJ.P. BraitehF. ChungC. TolaneyS.M. KuterI. NandaR. CassierP.A. DelordJ.P. GordonM.S. ElGabryE. ChangC.W. SarkarI. GrossmanW. O’HearC. FassòM. MolineroL. SchmidP. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer.JAMA Oncol.201951748210.1001/jamaoncol.2018.4224 30242306
     [Google Scholar]
  48. Head and Neck Cancers; Cleveland Clinic.USA2024
     [Google Scholar]
  49. Head and Neck Cancers.Frederick, MarylandNational Cancer Institute202115
     [Google Scholar]
  50. AndersonG. EbadiM. VoK. NovakJ. GovindarajanA. AminiA. An updated review on head and neck cancer treatment with radiation therapy.Cancers (Basel)20211319491210.3390/cancers13194912 34638398
     [Google Scholar]
  51. JohnsonD.E. BurtnessB. LeemansC.R. LuiV.W.Y. BaumanJ.E. GrandisJ.R. Head and neck squamous cell carcinoma.Nat. Rev. Dis. Primers2020619210.1038/s41572‑020‑00224‑3 33243986
     [Google Scholar]
  52. ModyM.D. RoccoJ.W. YomS.S. HaddadR.I. SabaN.F. Head and neck cancer.Lancet2021398103182289229910.1016/S0140‑6736(21)01550‑6 34562395
     [Google Scholar]
  53. HarringtonK.J. KongA. MachN. ChesneyJ.A. FernandezB.C. RischinD. CohenE.E.W. RadcliffeH.S. GumuscuB. ChengJ. SnyderW. SiuL.L. Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): A multicenter, phase 1b study.Clin. Cancer Res.202026195153516110.1158/1078‑0432.CCR‑20‑1170 32669371
     [Google Scholar]
  54. NishinoM. Giobbie-HurderA. GarganoM. SudaM. RamaiyaN.H. HodiF.S. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements.Clin. Cancer Res.201319143936394310.1158/1078‑0432.CCR‑13‑0895 23743568
     [Google Scholar]
  55. ChapmanP.B. EinhornL.H. MeyersM.L. SaxmanS. DestroA.N. PanageasK.S. BeggC.B. AgarwalaS.S. SchuchterL.M. ErnstoffM.S. HoughtonA.N. KirkwoodJ.M. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.J. Clin. Oncol.19991792745275110.1200/JCO.1999.17.9.2745 10561349
     [Google Scholar]
  56. LongG.V. StroyakovskiyD. GogasH. LevchenkoE. de BraudF. LarkinJ. GarbeC. JouaryT. HauschildA. GrobJ.J. SileniC.V. LebbeC. MandalàM. MillwardM. AranceA. BondarenkoI. HaanenJ.B.A.G. HanssonJ. UtikalJ. FerraresiV. KovalenkoN. MohrP. ProbachaiV. SchadendorfD. NathanP. RobertC. RibasA. DeMariniD.J. IraniJ.G. CaseyM. OuelletD. MartinA.M. LeN. PatelK. FlahertyK. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.N. Engl. J. Med.2014371201877188810.1056/NEJMoa1406037 25265492
     [Google Scholar]
  57. XiaA.L. WangX.C. LuY.J. LuX.J. SunB. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities.Oncotarget2017852905219053110.18632/oncotarget.19361 29163850
     [Google Scholar]
  58. RibasA. DummerR. PuzanovI. VanderWaldeA. AndtbackaR.H.I. MichielinO. OlszanskiA.J. MalvehyJ. CebonJ. FernandezE. KirkwoodJ.M. GajewskiT.F. ChenL. GorskiK.S. AndersonA.A. DiedeS.J. LassmanM.E. GansertJ. HodiF.S. LongG.V. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.Cell2017170611091119.e1010.1016/j.cell.2017.08.027 28886381
     [Google Scholar]
  59. JhawarS.R. WangS.J. ThandoniA. BommareddyP.K. NewmanJ.H. GiuriniE.F. MarzoA.L. KuzelT.M. GuptaV. ReiserJ. DanielsP. SchiffD. MitchellD. LeBoeufN.R. SimmonsC. GoyalS. LasfarA. Guevara-PatinoJ.A. HafftyB.G. KaufmanH.L. SilkA.W. ZlozaA. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.J. Immunother. Cancer202311700678010.1136/jitc‑2023‑006780 37433716
     [Google Scholar]
  60. BartlettD.L. LiuZ. SathaiahM. RavindranathanR. GuoZ. HeY. GuoZ.S. Oncolytic viruses as therapeutic cancer vaccines.Mol. Cancer201312110310.1186/1476‑4598‑12‑103 24020520
     [Google Scholar]
  61. EsakiS. GoshimaF. KimuraH. MurakamiS. NishiyamaY. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.Int. J. Cancer201313271592160110.1002/ijc.27823 22949155
     [Google Scholar]
  62. MondalM. GuoJ. HeP. ZhouD. Recent advances of oncolytic virus in cancer therapy.Hum. Vaccin. Immunother.202016102389240210.1080/21645515.2020.1723363 32078405
     [Google Scholar]
  63. KimR.D. SarkerD. MeyerT. YauT. MacarullaT. ParkJ.W. ChooS.P. HollebecqueA. SungM.W. LimH.Y. MazzaferroV. TrojanJ. ZhuA.X. YoonJ.H. SharmaS. LinZ.Z. ChanS.L. FaivreS. FeunL.G. YenC.J. DufourJ.F. PalmerD.H. LlovetJ.M. ManoogianM. TugnaitM. StranskyN. HagelM. KohlN.E. LengauerC. SherwinC.A. Schmidt-KittlerO. HoeflichK.P. ShiH. WolfB.B. KangY.K. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant fgf19 signaling as a driver event in hepatocellular carcinoma.Cancer Discov.20199121696170710.1158/2159‑8290.CD‑19‑0555 31575541
     [Google Scholar]
  64. WatanabeD. GoshimaF. MoriI. TamadaY. MatsumotoY. NishiyamaY. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.J. Dermatol. Sci.200850318519610.1016/j.jdermsci.2007.12.001 18226503
     [Google Scholar]
  65. ShimoyamaS. GoshimaF. TeshigaharaO. KasuyaH. KoderaY. NakaoA. NishiyamaY. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.Hepatogastroenterology2007547610381042 17629034
     [Google Scholar]
  66. FujimotoY. MizunoT. SugiuraS. GoshimaF. KohnoS.I. NakashimaT. NishiyamaY. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.Acta Otolaryngol.2006126101115111710.1080/00016480600702100 16923721
     [Google Scholar]
  67. LiangM. Clinical development of oncolytic viruses in China.Curr. Pharm. Biotechnol.20121391852185710.2174/138920112800958760 21740357
     [Google Scholar]
  68. RätyJ. PikkarainenJ. WirthT. Ylä-HerttualaS. Gene therapy: The first approved gene-based medicines, molecular mechanisms and clinical indications.Curr. Mol. Pharmacol.200811132310.2174/1874467210801010013 20021420
     [Google Scholar]
  69. CerulloV. KoskiA. Vähä-KoskelaM. HemminkiA. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: Data from mice, hamsters, and humans.Adv. Cancer Res.201211526531810.1016/B978‑0‑12‑398342‑8.00008‑2 23021247
     [Google Scholar]
  70. XiaZ.J. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.Chin. J. Cancer2004231216661670
     [Google Scholar]
  71. LiangM. Oncorine, the world first oncolytic virus medicine and its update in china.Curr. Cancer Drug Targets201818217117610.2174/1568009618666171129221503 29189159
     [Google Scholar]
  72. KirnD. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned?Gene Ther.200182899810.1038/sj.gt.3301377 11313778
     [Google Scholar]
  73. EndersJ.F. PeeblesT.C. Propagation in tissue cultures of cytopathogenic agents from patients with measles.Exp. Biol. Med.195486227728610.3181/00379727‑86‑21073 13177653
     [Google Scholar]
  74. EndersJ.F. KatzS.L. MilovanovicM.V. HollowayA. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: Technics for assay of effects of vaccination.N. Engl. J. Med.1960263415315910.1056/NEJM196007282630401 13820246
     [Google Scholar]
  75. MaderE.K. MaeyamaY. LinY. ButlerG.W. RussellH.M. GalanisE. RussellS.J. DietzA.B. PengK.W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.Clin. Cancer Res.200915237246725510.1158/1078‑0432.CCR‑09‑1292 19934299
     [Google Scholar]
  76. RussellS.J. FederspielM.J. PengK.W. TongC. DingliD. MoriceW.G. LoweV. O’ConnorM.K. KyleR.A. LeungN. BuadiF.K. RajkumarS.V. GertzM.A. LacyM.Q. DispenzieriA. Remission of disseminated cancer after systemic oncolytic virotherapy.Mayo Clin. Proc.201489792693310.1016/j.mayocp.2014.04.003 24835528
     [Google Scholar]
  77. HaddadD. Genetically engineered vaccinia viruses as agents for cancer treatment, imaging, and transgene delivery.Front. Oncol.201779610.3389/fonc.2017.00096 28589082
     [Google Scholar]
  78. ParatoK.A. BreitbachC.J. Le BoeufF. WangJ. StorbeckC. IlkowC. DialloJ.S. FallsT. BurnsJ. GarciaV. KanjiF. EvginL. HuK. ParadisF. KnowlesS. HwangT.H. VanderhydenB.C. AuerR. KirnD.H. BellJ.C. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Mol. Ther.201220474975810.1038/mt.2011.276 22186794
     [Google Scholar]
  79. HwangT.H. MoonA. BurkeJ. RibasA. StephensonJ. BreitbachC.J. DaneshmandM. De SilvaN. ParatoK. DialloJ.S. LeeY.S. LiuT.C. BellJ.C. KirnD.H. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.Mol. Ther.201119101913192210.1038/mt.2011.132 21772252
     [Google Scholar]
  80. ParkB.H. HwangT. LiuT.C. SzeD.Y. KimJ.S. KwonH.C. OhS.Y. HanS.Y. YoonJ.H. HongS.H. MoonA. SpethK. ParkC. AhnY.J. DaneshmandM. RheeB.G. PinedoH.M. BellJ.C. KirnD.H. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial.Lancet Oncol.20089653354210.1016/S1470‑2045(08)70107‑4 18495536
     [Google Scholar]
  81. VargheseS. RabkinS.D. LiuR. NielsenP.G. IpeT. MartuzaR.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.Cancer Gene Ther.200613325326510.1038/sj.cgt.7700900 16179929
     [Google Scholar]
  82. BommareddyP.K. AspromonteS. ZlozaA. RabkinS.D. KaufmanH.L. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.Sci. Transl. Med.201810471eaau041710.1126/scitranslmed.aau0417 30541787
     [Google Scholar]
  83. WakimotoH. IkedaK. AbeT. IchikawaT. HochbergF.H. EzekowitzR.A.B. PasternackM.S. ChioccaE.A. The complement response against an oncolytic virus is species-specific in its activation pathways.Mol. Ther.20025327528210.1006/mthe.2002.0547 11863417
     [Google Scholar]
  84. TerasawaY. HotaniT. KatayamaY. TachibanaM. MizuguchiH. SakuraiF. Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.Cancer Gene Ther.201522418819710.1038/cgt.2015.4 25633482
     [Google Scholar]
  85. LiikanenI. KoskiA. Merisalo-SoikkeliM. HemminkiO. OksanenM. KairemoK. JoensuuT. KanervaA. HemminkiA. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.OncoImmunology20154398977110.4161/2162402X.2014.989771 25949903
     [Google Scholar]
  86. Garcia-CarboneroR. SalazarR. DuranI. Osman-GarciaI. Paz-AresL. BozadaJ.M. BoniV. BlancC. SeymourL. BeadleJ. AlvisS. ChampionB. CalvoE. FisherK. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.J. Immunother. Cancer2017517110.1186/s40425‑017‑0277‑7 28923104
     [Google Scholar]
  87. KennedyE.M. DenslowA. HewettJ. KongL. De AlmeidaA. BryantJ.D. LeeJ.S. JacquesJ. FeauS. HayesM. McMichaelE.L. WambuaD. FarkalyT. RahmehA.A. HerschelmanL. DouglasD. SpinaleJ. AdhikariS. DeterlingJ. ScottM. HainesB.B. FinerM.H. AshburnT.T. QuévaC. LernerL. Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.Nat. Commun.2022131590710.1038/s41467‑022‑33599‑w 36207308
     [Google Scholar]
  88. SamsonA. WestE.J. CarmichaelJ. ScottK.J. TurnbullS. KuszlewiczB. DaveR.V. Peckham-CooperA. TidswellE. KingstonJ. JohnpulleM. da SilvaB. JenningsV.A. BendjamaK. StojkowitzN. LuskyM. PrasadK.R. ToogoodG.J. AuerR. BellJ. TwelvesC.J. HarringtonK.J. VileR.G. PandhaH. Errington-MaisF. RalphC. NewtonD.J. AnthoneyA. MelcherA.A. CollinsonF. Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients.Cancer Immunol. Res.202210674575610.1158/2326‑6066.CIR‑21‑0171 35439304
     [Google Scholar]
  89. YunC.O. Overcoming the extracellular matrix barrier to improve intratumoral spread and therapeutic potential of oncolytic virotherapy.Curr. Opin. Mol. Ther.2008104356361 18683100
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206379105250429115604
Loading
Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types
Anti-Cancer Agents in Medicinal Chemistry 26, 175 (2026); https://doi.org/10.2174/0118715206379105250429115604
/content/journals/acamc/10.2174/0118715206379105250429115604
/content/journals/acamc/10.2174/0118715206379105250429115604
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer immunotherapy; combination therapy; immune checkpoint inhibitors; melanoma treatment; oncolytic viral therapy; Talimogene laherparepvec (T-VEC)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test